Long COVID Antiviral-Antibody Therapy for Multi-Symptom PASC

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a lack of effective treatments for post-acute sequelae of COVID-19 (PASC), commonly known as 'long COVID', which presents with a variety of persistent symptoms weeks or months after the initial infection, and existing treatments are inadequate.

Innovation Solution

Administering a combination of antiviral agents, such as protease inhibitors and monoclonal antibodies, along with optional additional active agents like amino acids, antioxidants, and immunostimulants, to target and alleviate the symptoms of PASC.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If combination therapy with antiviral agents and antibodies is administered, then the incidence and severity of PASC symptoms are significantly reduced, but the complexity of treatment regimen increases

Engineering Contradiction:

Improveeffectiveness in reducing PASC symptomsVSAvoidcomplexity of treatment regimen

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The treatment is divided into multiple components: first antiviral agent, second antiviral agent, first antibody, and second antibody, each targeting different aspects of viral infection and immune response. This segmentation allows comprehensive coverage of PASC mechanisms while maintaining manageable individual agent characteristics

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

Multiple antiviral agents and antibodies are combined in a single therapy regimen to achieve synergistic effects. The combination targets both direct viral replication and immune-mediated pathology, providing comprehensive treatment coverage that cannot be achieved with single agents

Inventive Principle:

Principle #5Merging (Combining)

2Reliability

If multiple antiviral agents and antibodies are combined, then treatment efficacy against PASC improves, but the cost of treatment increases

Engineering Contradiction:

Improvetreatment efficacyVSAvoidcost of treatment

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The combination therapy addresses multiple PASC symptoms and mechanisms simultaneously through agents with broad spectrums of activity. Antiviral agents target viral replication while antibodies address immune-mediated pathology, providing multi-functional treatment coverage that reduces the need for multiple separate therapies

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Adaptability or versatility

If combination therapy is administered to target multiple PASC symptoms, then symptom coverage increases, but the difficulty of monitoring and managing treatment effects increases

Engineering Contradiction:

Improvesymptom coverageVSAvoidmonitoring treatment effects

Core Design Contradiction:

Adaptability or versatilityVSDifficulty of detecting and measuring

Solution Approach 1:

The treatment regimen incorporates monitoring of treatment effects and adjustment of therapy based on patient response. Biomarker assessment and symptom tracking enable real-time feedback to optimize the combination therapy, allowing clinicians to adjust dosing or sequencing based on individual patient progress

Inventive Principle:

Principle #23Feedback

Data Source

PatentUS20250236660A1Therapeutic combinations and methods to treat long covid

Publication Date: 2025.07.24 DIXIT ROHAN

AI summary

The disclosure relates in some aspects to methods of treating a subject having post-acute sequelae of COVID-19 (PASC), sometimes also known as “long COVID.” Also provided are pharmaceutical combinations for treating a subject having PASC, such as using one or more antiviral agents and one or more antibodies, as well as kits used with disclosed pharmaceutical combinations and in disclosed methods.